On the stock market since 2011, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 9% a year over the last 4 years. Red columns mark years that ended in a loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $56.1M a year. A small number, but proof the product has real buyers.
It pays out $0.45 per share each year — regular cash for whoever holds the stock.
A loss of $25.7M against $56.1M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, PCARX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PCARX is a high-risk stock — not yet profitable, and its future rides on its product catching on.